{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:48:07Z","timestamp":1793486887649,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002869","name":"Christian-Albrechts-Universit\u00e4t zu Kiel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metastasis and therapy resistance are main clinical challenges of pancreatic ductal adenocarcinoma (PDAC) still limiting patient`s prognosis. Both are dependent on tumor cell plasticity, which allows rapid adaptation of tumor cells to changing microenvironmental conditions. Epithelial-Mesenchymal-Transition (EMT), a process by which carcinoma cells acquire invasive abilities, is associated with a gain of cancer stem cell (CSC) properties. Different CSC phenotypes were described in PDAC, whereby high levels of the CSC marker Nestin was identified in CSC clones of mesenchymal Panc1 cells, while CSC clones of epithelial Panc89 cells were characterized by a high SOX2 expression. To investigate the functional impact of these CSC markers in PDAC cells with different EMT phenotypes, expression of either CSC marker was silenced in heterogenous (parental) and CSC PDAC populations to analyze their impact on essential malignancy associated properties.<\/jats:p>\n                  <jats:p>\n                    SiRNA-mediated knockdown (KD) of\n                    <jats:italic>NES<\/jats:italic>\n                    and\/or\n                    <jats:italic>SOX2<\/jats:italic>\n                    in Panc1 and Panc89 cell variants (parental and CSC population), respectively, was successfully achieved. Decreased\n                    <jats:italic>NES<\/jats:italic>\n                    expression in Panc1 cell variants and decreased\n                    <jats:italic>SOX2<\/jats:italic>\n                    expression in Panc89 cell variants significantly inhibited self-renewing properties, however, only marginally impacted cell growth, EMT marker expression, migration and invasion properties as well as response to chemotherapy. Overall, our data indicate that Nestin and SOX2 are crucial mediators of self-renewal capabilities of mesenchymal and epithelial PDAC cell variants, respectively, but that further factors are required for the maintenance of other malignancy associated properties.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s12015-025-11006-3","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:10:59Z","timestamp":1761199859000},"page":"620-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nestin and SOX2 Maintain self-renewal Abilities of Different Pancreatic Cancer Stem Cell Populations"],"prefix":"10.1007","volume":"22","author":[{"given":"Lisa-Marie","family":"Philipp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Hattingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6582-0083","authenticated-orcid":false,"given":"Susanne","family":"Sebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"11006_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"no. October 202","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025). Cancer statistics, 2025. C Ca: A Cancer Journal for Clinicians, no. October 2024, 10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"C Ca: A Cancer Journal for Clinicians"},{"issue":"11","key":"11006_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united States. Cancer Research, 74(11), 2913\u20132921. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155","journal-title":"Cancer Research"},{"key":"11006_CR3","doi-asserted-by":"publisher","unstructured":"Meslar, E. (Sep. 2020). Pancreatic adenocarcinoma. Jaapa : official Journal of the American Academy of Physician Assistants, 33(11), 50\u201351. https:\/\/doi.org\/10.1097\/01.JAA.0000718300.59420.6c","DOI":"10.1097\/01.JAA.0000718300.59420.6c"},{"issue":"2","key":"11006_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s002689900215","volume":"21","author":"C Sperti","year":"1997","unstructured":"Sperti, C., Pasquali, C., Piccoli, A., & Pedrazzoli, S. (1997). Recurrence after resection for ductal adenocarcinoma of the pancreas. World Journal of Surgery, 21(2), 195\u2013200. https:\/\/doi.org\/10.1007\/s002689900215","journal-title":"World Journal of Surgery"},{"issue":"6","key":"11006_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ejso.2008.12.006","volume":"35","author":"A Van den broeck","year":"2009","unstructured":"Van den broeck, A., Sergeant, G., Ectors, N., Van Steenbergen, W., Aerts, R., & Topal, B. (2009). Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology, 35(6), 600\u2013604. https:\/\/doi.org\/10.1016\/j.ejso.2008.12.006","journal-title":"European Journal of Surgical Oncology"},{"issue":"5","key":"11006_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot, V. P., et al. (2018). Patterns, Timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Annals of Surgery, 267(5), 936\u2013945. https:\/\/doi.org\/10.1097\/SLA.0000000000002234","journal-title":"Annals of Surgery"},{"issue":"11","key":"11006_CR7","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/bjs.11003","volume":"105","author":"MD Chiaro","year":"2018","unstructured":"Chiaro, M. D., & S\u00f8reide, K. (2018). Trials and tribulations of neoadjuvant therapy in pancreatic cancer. British Journal of Surgery, 105(11), 1387\u20131389. https:\/\/doi.org\/10.1002\/bjs.11003","journal-title":"British Journal of Surgery"},{"issue":"10","key":"11006_CR8","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/annonc\/mdi309","volume":"16","author":"H Oettle","year":"2005","unstructured":"Oettle, H., et al. (2005). A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Annals of Oncology, 16(10), 1639\u20131645. https:\/\/doi.org\/10.1093\/annonc\/mdi309","journal-title":"Annals of Oncology"},{"key":"11006_CR9","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/nejmoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine, 364, 1817\u20131825. https:\/\/doi.org\/10.1056\/nejmoa1011923","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"11006_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12029-017-0028-5","volume":"50","author":"Y Wang","year":"2019","unstructured":"Wang, Y., Camateros, P., Cheung, W. Y., & Real-World, A. (2019). Comparison of FOLFIRINOX, gemcitabine plus nab-Paclitaxel, and gemcitabine in advanced pancreatic cancers. J Gastrointest Cancer, 50(1), 62\u201368. https:\/\/doi.org\/10.1007\/s12029-017-0028-5","journal-title":"J Gastrointest Cancer"},{"issue":"5","key":"11006_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.6004\/jnccn.2021.7028","volume":"20","author":"EN Pijnappel","year":"2022","unstructured":"Pijnappel, E. N., et al. (2022). First- and Second-Line palliative systemic treatment outcomes in a Real-World metastatic pancreatic cancer cohort. JNCCN J Natl Compr Cancer Netw, 20(5), 443\u2013450. https:\/\/doi.org\/10.6004\/jnccn.2021.7028","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"11006_CR12","unstructured":"Krebsgesellschaft, A., & Krebshilfe, D. (2021). Konsultationsfassung S3-Leitlinie zum exokrinen Pankreaskarzinom Wesentliche Neuerungen durch die Aktualisierung, vol. 01, no. September, pp. 1\u2013220."},{"issue":"2","key":"11006_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: Molecular insights and evolving paradigms. Cell, 147(2), 275\u2013292. https:\/\/doi.org\/10.1016\/j.cell.2011.09.024","journal-title":"Cell"},{"key":"11006_CR14","doi-asserted-by":"publisher","unstructured":"Toh, B., et al. (2011). Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. Plos Biology, 9(9). https:\/\/doi.org\/10.1371\/journal.pbio.1001162","DOI":"10.1371\/journal.pbio.1001162"},{"issue":"4","key":"11006_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrc2622","volume":"9","author":"DX Nguyen","year":"2009","unstructured":"Nguyen, D. X., Bos, P. D., & Massagu\u00e9, J. (2009). Metastasis: From dissemination to organ-specific colonization. Nature Reviews Cancer, 9(4), 274\u2013284. https:\/\/doi.org\/10.1038\/nrc2622","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"11006_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0937-3","volume":"18","author":"G S\u00f6keland","year":"2019","unstructured":"S\u00f6keland, G., & Schumacher, U. (2019). The functional role of integrins during intra- and extravasation within the metastatic cascade. Molecular Cancer, 18(1), 1\u201319. https:\/\/doi.org\/10.1186\/s12943-018-0937-3","journal-title":"Molecular Cancer"},{"key":"11006_CR17","doi-asserted-by":"publisher","unstructured":"Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009). Epithelial-Mesenchymal Transitions in Development and Disease, Cell, vol. 139, no. 5. Sinauer Associates, Inc., Sunderland, MA, pp. 871\u2013890, Nov. https:\/\/doi.org\/10.1016\/j.cell.2009.11.007","DOI":"10.1016\/j.cell.2009.11.007"},{"issue":"12","key":"11006_CR18","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/bjc.2015.177","volume":"112","author":"JA Galv\u00e1n","year":"2015","unstructured":"Galv\u00e1n, J. A., et al. (2015). Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer. British Journal of Cancer, 112(12), 1944\u20131950. https:\/\/doi.org\/10.1038\/bjc.2015.177","journal-title":"British Journal of Cancer"},{"key":"11006_CR19","doi-asserted-by":"publisher","unstructured":"Nieto, M. A., Huang, R. Y. Y. J., Jackson, R. A. A., & Thiery, J. P. P. (2016). Emt: Cell, vol. 166, no. 1, pp. 21\u201345, 2016. https:\/\/doi.org\/10.1016\/j.cell.2016.06.028","DOI":"10.1016\/j.cell.2016.06.028"},{"issue":"10","key":"11006_CR20","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1158\/0008-5472.CAN-08-3493","volume":"69","author":"C Geismann","year":"2009","unstructured":"Geismann, C., et al. (2009). Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor \u03b21- and slug-dependent: Role in malignant transformation of pancreatic cancer. Cancer Research, 69(10), 4517\u20134526. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3493","journal-title":"Cancer Research"},{"key":"11006_CR21","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1038\/sj.onc.1210076","volume":"26","author":"S Sebens","year":"2007","unstructured":"Sebens, S., M\u00fcerk\u00f6ster, et al. (2007). Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene, 26, 2759\u20132768. https:\/\/doi.org\/10.1038\/sj.onc.1210076","journal-title":"Oncogene"},{"key":"11006_CR22","doi-asserted-by":"publisher","unstructured":"Wei, T. (2019). Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer, Cancer Lett., vol. 452, no. March, pp. 237\u2013243. https:\/\/doi.org\/10.1016\/j.canlet.2019.03.009","DOI":"10.1016\/j.canlet.2019.03.009"},{"issue":"9","key":"11006_CR23","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-14-2535","volume":"75","author":"MJ Schliekelman","year":"2015","unstructured":"Schliekelman, M. J., et al. (2015). Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. Cancer Research, 75(9), 1789\u20131800. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2535","journal-title":"Cancer Research"},{"issue":"10","key":"11006_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0076773","volume":"8","author":"H Roca","year":"2013","unstructured":"Roca, H., et al. (2013). Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS One, 8(10), 1\u201320. https:\/\/doi.org\/10.1371\/journal.pone.0076773","journal-title":"PLoS One"},{"issue":"02","key":"11006_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.4172\/2155-9929.s3-002","volume":"03","author":"M Watanabe","year":"2012","unstructured":"Watanabe, M. (2012). Metabolic profiling comparison of human pancreatic ductal epithelial cells and three pancreatic cancer cell lines using NMR based metabonomics. J Mol Biomark Diagn, 03(02), 513\u2013529. https:\/\/doi.org\/10.4172\/2155-9929.s3-002","journal-title":"J Mol Biomark Diagn"},{"key":"11006_CR26","doi-asserted-by":"publisher","unstructured":"Xia, L., et al. (January, 2021). OVOL2 attenuates the expression of MAP3K8 to suppress epithelial mesenchymal transition in colorectal cancer. Pathology, Research and Practice, 224, no.. https:\/\/doi.org\/10.1016\/j.prp.2021.153493","DOI":"10.1016\/j.prp.2021.153493"},{"key":"11006_CR27","doi-asserted-by":"publisher","unstructured":"Scott, C. L., & Omilusik, K. D. (2019). ZEBs: Novel Players in Immune Cell Development and Function, Trends in Immunology, vol. 40, no. 5. Elsevier Ltd, pp. 431\u2013446. https:\/\/doi.org\/10.1016\/j.it.2019.03.001","DOI":"10.1016\/j.it.2019.03.001"},{"key":"11006_CR28","doi-asserted-by":"publisher","unstructured":"Zhang, Y., Xu, L., Li, A., & Han, X. (2019). The roles of ZEB1 in tumorigenic progression and epigenetic modifications, Biomedicine and Pharmacotherapy, vol. 110, no. November 2018. Elsevier, pp. 400\u2013408. https:\/\/doi.org\/10.1016\/j.biopha.2018.11.112","DOI":"10.1016\/j.biopha.2018.11.112"},{"issue":"9","key":"11006_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pbio.3001394","volume":"19","author":"J Wang","year":"2021","unstructured":"Wang, J., et al. (2021). Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity. Plos Biology, 19(9), 1\u201333. https:\/\/doi.org\/10.1371\/journal.pbio.3001394","journal-title":"Plos Biology"},{"issue":"4","key":"11006_CR30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027.The","volume":"16","author":"S Mani","year":"2008","unstructured":"Mani, S., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 16(4), 704\u2013715. https:\/\/doi.org\/10.1016\/j.cell.2008.03.027.The","journal-title":"Cell"},{"issue":"2","key":"11006_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.molonc.2015.10.002","volume":"10","author":"F Andriani","year":"2016","unstructured":"Andriani, F., et al. (2016). Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells. Molecular Oncology, 10(2), 253\u2013271. https:\/\/doi.org\/10.1016\/j.molonc.2015.10.002","journal-title":"Molecular Oncology"},{"key":"11006_CR32","doi-asserted-by":"publisher","unstructured":"Valle, S., Martin-Hijano, L., Alcal\u00e1, S., Alonso-Nocelo, M., & Sainz, B. (2018). The ever-evolving concept of the cancer stem cell in pancreatic cancer. Cancers (Basel), 10(2). https:\/\/doi.org\/10.3390\/cancers10020033","DOI":"10.3390\/cancers10020033"},{"key":"11006_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cell.2012.12.012","volume":"152","author":"S Schwitalla","year":"2013","unstructured":"Schwitalla, S., et al. (2013). Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell, 152, 1\u20132. https:\/\/doi.org\/10.1016\/j.cell.2012.12.012","journal-title":"Cell"},{"key":"11006_CR34","doi-asserted-by":"publisher","unstructured":"Jolly, M. K., Tripathi, S. C., Jia, D., Mooney, S. M., Celiktas, M., Hanash, S. M., Mani, S. A., Pienta, K. J., Ben-Jacob, E., & Levine, H. (2016). Stability of the hybrid epithelial\/mesenchymal phenotype. Oncotarget, 7(19), 27067\u201327084. https:\/\/doi.org\/10.18632\/oncotarget.8166","DOI":"10.18632\/oncotarget.8166"},{"issue":"7","key":"11006_CR35","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/1878-0261.12083","volume":"11","author":"MK Jolly","year":"2017","unstructured":"Jolly, M. K., Ware, K. E., Gilja, S., Somarelli, J. A., & Levine, H. (2017). EMT and MET: Necessary or permissive for metastasis? Molecular Oncology, 11(7), 755\u2013769. https:\/\/doi.org\/10.1002\/1878-0261.12083","journal-title":"Molecular Oncology"},{"key":"11006_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/0717-6287-47-66","volume":"47","author":"L Fulawka","year":"2014","unstructured":"Fulawka, L., Donizy, P., & Halon, A. (2014). Cancer stem cells\u2013the current status of an old concept: Literature review and clinical approaches. Biological Research, 47, 66. https:\/\/doi.org\/10.1186\/0717-6287-47-66","journal-title":"Biological Research"},{"key":"11006_CR37","doi-asserted-by":"publisher","unstructured":"Kreso, A., & Dick, J. E. (2014). Evolution of the cancer stem cell model, Cell Stem Cell, vol. 14, no. 3. Elsevier Inc., pp. 275\u2013291. https:\/\/doi.org\/10.1016\/j.stem.2014.02.006","DOI":"10.1016\/j.stem.2014.02.006"},{"issue":"1","key":"11006_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/eva.12017","volume":"6","author":"M Greaves","year":"2013","unstructured":"Greaves, M. (2013). Cancer stem cells as \u2018units of selection\u2019. Evolutionary Applications, 6(1), 102\u2013108. https:\/\/doi.org\/10.1111\/eva.12017","journal-title":"Evolutionary Applications"},{"key":"11006_CR39","doi-asserted-by":"publisher","unstructured":"Chaffer, C. L. (2011). Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state, Proc. Natl. Acad. Sci. U. S. A., vol. 108, no. 19, pp. 7950\u20137955. https:\/\/doi.org\/10.1073\/pnas.1102454108","DOI":"10.1073\/pnas.1102454108"},{"issue":"3","key":"11006_CR40","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3892\/ijo.2014.2796","volume":"46","author":"ED Pozza","year":"2015","unstructured":"Pozza, E. D., et al. (2015). Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi-directionally convert into cancer stem cells. International Journal of Oncology, 46(3), 1099\u20131108. https:\/\/doi.org\/10.3892\/ijo.2014.2796","journal-title":"International Journal of Oncology"},{"issue":"3","key":"11006_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ejso.2015.12.008","volume":"42","author":"DP O\u2019Leary","year":"2016","unstructured":"O\u2019Leary, D. P., O\u2019Leary, E., Foley, N., Cotter, T. G., Wang, J. H., & Redmond, H. P. (2016). Effects of surgery on the cancer stem cell niche. European Journal of Surgical Oncology, 42(3), 319\u2013325. https:\/\/doi.org\/10.1016\/j.ejso.2015.12.008","journal-title":"European Journal of Surgical Oncology"},{"issue":"37","key":"11006_CR42","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1038\/onc.2016.26","volume":"35","author":"S Mukherjee","year":"2016","unstructured":"Mukherjee, S., et al. (2016). Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4\u2009+\u2009migrating cancer stem cells. Oncogene, 35(37), 4937\u20134948. https:\/\/doi.org\/10.1038\/onc.2016.26","journal-title":"Oncogene"},{"key":"11006_CR43","doi-asserted-by":"publisher","unstructured":"Philipp, L. M. (2024). Feb., Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Different Metastatic Propensities, Cancers (Basel)., vol. 16, no. 4, p. 686. https:\/\/doi.org\/10.3390\/cancers16040686","DOI":"10.3390\/cancers16040686"},{"issue":"3","key":"11006_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10555-021-09979-x","volume":"40","author":"K Patil","year":"2021","unstructured":"Patil, K., Khan, F. B., Akhtar, S., Ahmad, A., & Uddin, S. (2021). The plasticity of pancreatic cancer stem cells: Implications in therapeutic resistance. Cancer and Metastasis Reviews, 40(3), 691\u2013720. https:\/\/doi.org\/10.1007\/s10555-021-09979-x","journal-title":"Cancer and Metastasis Reviews"},{"issue":"1","key":"11006_CR45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.7150\/jca.88397","volume":"15","author":"Y Ding","year":"2024","unstructured":"Ding, Y., et al. (2024). Pan-Cancer analysis reveals SOX2 as a promising prognostic and immunotherapeutic biomarker across various cancer Types, including pancreatic cancer. Journal of Cancer, 15(1), 251\u2013274. https:\/\/doi.org\/10.7150\/jca.88397","journal-title":"Journal of Cancer"},{"key":"11006_CR46","doi-asserted-by":"publisher","unstructured":"Szyma\u0144ska-Chabowska, A., \u015awi\u0105tkowski, F., Jankowska-Pola\u0144ska, B., Mazur, G., & Chabowski, M. (2021). Nestin expression as a diagnostic and prognostic marker in colorectal cancer and other tumors. Clin Med Insights Oncol, 15. https:\/\/doi.org\/10.1177\/11795549211038256","DOI":"10.1177\/11795549211038256"},{"issue":"60","key":"11006_CR47","doi-asserted-by":"publisher","first-page":"31771","DOI":"10.18632\/oncotarget.25884","volume":"9","author":"H Knaack","year":"2018","unstructured":"Knaack, H., et al. (2018). Liver metastasis of pancreatic cancer: The hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells. Oncotarget, 9(60), 31771\u201331786. https:\/\/doi.org\/10.18632\/oncotarget.25884","journal-title":"Oncotarget"},{"key":"11006_CR48","doi-asserted-by":"publisher","unstructured":"Lu, Y., et al. (Oct. 2013). Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Cancer Letters, 340(1), 113\u2013123. Lu Y, Zhu H, Shan H, Lu J, Chang X, Li X, Lu J, Fan X, Zhu S, Wang Y, Guo Q, Wang L, Huang Y, Zhu M, Wang Z. Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Cancer Lett. 2013 Oct 28;340(1):113-23. doi: 10.1016\/j.canlet.2013.07.009. Epub 2013 Jul 17. PMID: 23872274. https:\/\/doi.org\/10.1016\/j.canlet.2013.07.009","DOI":"10.1016\/j.canlet.2013.07.009"},{"key":"11006_CR49","doi-asserted-by":"crossref","unstructured":"Su, H. T. (2013). Stem cell marker Nestin is critical for TGF-beta1-mediated tumor progression in pancreatic cancer. Molecular Cancer Research, 11.","DOI":"10.1158\/1541-7786.MCR-12-0511"},{"issue":"5","key":"11006_CR50","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4161\/cbt.11.5.14673","volume":"11","author":"Y Matsuda","year":"2011","unstructured":"Matsuda, Y., Naito, Z., Kawahara, K., Nakazawa, N., Korc, M., & Ishiwata, T. (2011). Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Cancer Biology & Therapy, 11(5), 512\u2013523. https:\/\/doi.org\/10.4161\/cbt.11.5.14673","journal-title":"Cancer Biology & Therapy"},{"issue":"1","key":"11006_CR51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/MPA.0000000000000427","volume":"45","author":"Y Matsuda","year":"2016","unstructured":"Matsuda, Y., Ishiwata, T., Yoshimura, H., Yamashita, S., Ushijima, T., & Arai, T. (2016). Systemic administration of small interfering RNA targeting human Nestin inhibits pancreatic cancer cell proliferation and metastasis. Pancreas, 45(1), 93\u2013100. https:\/\/doi.org\/10.1097\/MPA.0000000000000427","journal-title":"Pancreas"},{"issue":"2","key":"11006_CR52","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.mpa.0000202947.80117.a0","volume":"32","author":"Y Sanada","year":"2006","unstructured":"Sanada, Y., Yoshida, K., Ohara, M., Oeda, M., Konishi, K., & Tsutani, Y. (2006). Histopathologic evaluation of Stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: Comparison of expression patterns between invasive components and cancerous or nonneoplastic Intr. Pancreas, 32(2), 164\u2013170. https:\/\/doi.org\/10.1097\/01.mpa.0000202947.80117.a0","journal-title":"Pancreas"},{"key":"11006_CR53","doi-asserted-by":"publisher","unstructured":"Han, X., et al. (2012). Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients. PLoS One, 7(8). https:\/\/doi.org\/10.1371\/journal.pone.0041335","DOI":"10.1371\/journal.pone.0041335"},{"key":"11006_CR54","doi-asserted-by":"publisher","unstructured":"Herreros-Villanueva, M., et al. (June, 2013). SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis, 2, no.. https:\/\/doi.org\/10.1038\/oncsis.2013.23","DOI":"10.1038\/oncsis.2013.23"},{"key":"11006_CR55","doi-asserted-by":"publisher","unstructured":"Beaver, C. M., Ahmed, A., & Masters, J. R. (2014). Clonogenicity: Holoclones and meroclones contain stem cells. PLoS One, 9(2). https:\/\/doi.org\/10.1371\/journal.pone.0089834","DOI":"10.1371\/journal.pone.0089834"},{"issue":"11","key":"11006_CR56","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/pin.12447","volume":"66","author":"T Ishiwata","year":"2016","unstructured":"Ishiwata, T. (2016). Cancer stem cells and epithelial-mesenchymal transition: Novel therapeutic targets for cancer. Pathology International, 66(11), 601\u2013608. https:\/\/doi.org\/10.1111\/pin.12447","journal-title":"Pathology International"},{"key":"11006_CR57","doi-asserted-by":"publisher","unstructured":"Paul, R., Dorsey, J. F., & Fan, Y. (2022). Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications, Pharmacol. Ther., vol. 231, no. xxxx, p. 107985. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107985","DOI":"10.1016\/j.pharmthera.2021.107985"},{"key":"11006_CR58","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3389\/fonc.2012.00209","volume":"2 JAN","author":"E Karamitopoulou","year":"2013","unstructured":"Karamitopoulou, E. (2013). Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Frontiers in Oncology, 2 JAN, 2009\u20132013. https:\/\/doi.org\/10.3389\/fonc.2012.00209","journal-title":"Frontiers in Oncology"},{"issue":"2","key":"11006_CR59","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.canlet.2014.12.004","volume":"357","author":"H xiang Zhan","year":"2015","unstructured":"xiang Zhan, H., wei Xu, J., Wu, D., Zhang, T., & yuan Hu, S. (2015). Pancreatic cancer stem cells: New insight into a stubborn disease. Cancer Letters, 357(2), 429\u2013437. https:\/\/doi.org\/10.1016\/j.canlet.2014.12.004","journal-title":"Cancer Letters"},{"key":"11006_CR60","doi-asserted-by":"publisher","unstructured":"Pushalkar, S., et al. (Apr. 2018). The pancreatic cancer Microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discovery, 8(4), 403\u2013416. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1134","DOI":"10.1158\/2159-8290.CD-17-1134"},{"key":"11006_CR61","doi-asserted-by":"publisher","unstructured":"Riquelme, E., et al. (Aug. 2019). Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell, 178(4), 795\u2013806. https:\/\/doi.org\/10.1016\/j.cell.2019.07.008. .e12.","DOI":"10.1016\/j.cell.2019.07.008"},{"key":"11006_CR62","doi-asserted-by":"publisher","unstructured":"Guo, W., et al. (Dec. 2021). Tumor Microbiome contributes to an aggressive phenotype in the basal-like subtype of pancreatic cancer. Commun Biol, 4(1). https:\/\/doi.org\/10.1038\/s42003-021-02557-5","DOI":"10.1038\/s42003-021-02557-5"},{"issue":"9","key":"11006_CR63","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1136\/gutjnl-2015-309304","volume":"64","author":"A Neesse","year":"2015","unstructured":"Neesse, A., Alg\u00fcl, H., Tuveson, D. A., & Gress, T. M. (2015). Stromal biology and therapy in pancreatic cancer: A changing paradigm. Gut, 64(9), 1476\u20131484. https:\/\/doi.org\/10.1136\/gutjnl-2015-309304","journal-title":"Gut"},{"issue":"1","key":"11006_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-023-02693-2","volume":"42","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y., et al. (2023). Pancreatic cancer stemness: Dynamic status in malignant progression. Journal of Experimental & Clinical Cancer Research : Cr, 42(1), 1\u201319. https:\/\/doi.org\/10.1186\/s13046-023-02693-2","journal-title":"Journal of Experimental & Clinical Cancer Research : Cr"},{"issue":"7","key":"11006_CR65","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/2159-8290.CD-19-0015","volume":"9","author":"S Yuan","year":"2019","unstructured":"Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019). Cellular plasticity in cancer. Cancer Discovery, 9(7), 837\u2013851. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0015","journal-title":"Cancer Discovery"},{"issue":"5","key":"11006_CR66","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009). Epithelial-Mesenchymal transitions in development and disease. Cell, 139(5), 871\u2013890. https:\/\/doi.org\/10.1016\/j.cell.2009.11.007","journal-title":"Cell"},{"issue":"6","key":"11006_CR67","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ccr.2012.11.009","volume":"22","author":"T Brabletz","year":"2012","unstructured":"Brabletz, T. (2012). Cancer cell previews EMT and MET in metastasis: Where are the cancer stem cells? Ccell, 22(6), 699\u2013701. https:\/\/doi.org\/10.1016\/j.ccr.2012.11.009","journal-title":"Ccell"},{"issue":"4","key":"11006_CR68","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027.The","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani, S. A., et al. (2008). EMT creates cells with the properties of stem cells. Cell, 133(4), 704\u2013715. https:\/\/doi.org\/10.1016\/j.cell.2008.03.027.The","journal-title":"Cell"},{"issue":"4","key":"11006_CR69","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani, S. A., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704\u2013715. https:\/\/doi.org\/10.1016\/j.cell.2008.03.027","journal-title":"Cell"},{"issue":"3","key":"11006_CR70","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","volume":"1","author":"PC Hermann","year":"2007","unstructured":"Hermann, P. C., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3), 313\u2013323. https:\/\/doi.org\/10.1016\/j.stem.2007.06.002","journal-title":"Cell Stem Cell"},{"issue":"3","key":"11006_CR71","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","volume":"67","author":"C Li","year":"2007","unstructured":"Li, C., et al. (2007). Identification of pancreatic cancer stem cells. Cancer Research, 67(3), 1030\u20131037. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2030","journal-title":"Cancer Research"},{"key":"11006_CR72","doi-asserted-by":"publisher","unstructured":"Burdziak, C., et al. (May 2023). Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis. Science, 380, eadd5327. https:\/\/doi.org\/10.1126\/science.add5327. no. 6645.","DOI":"10.1126\/science.add5327"},{"issue":"5","key":"11006_CR73","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00428-003-0784-4","volume":"442","author":"B Sipos","year":"2003","unstructured":"Sipos, B., M\u00f6ser, S., Kalthoff, H., T\u00f6r\u00f6k, V., L\u00f6hr, M., & Kl\u00f6ppel, G. (2003). A comprehensive characterization of pancreatic ductal carcinoma cell lines: Towards the establishment of an in vitro research platform. Virchows Archiv, 442(5), 444\u2013452. https:\/\/doi.org\/10.1007\/s00428-003-0784-4","journal-title":"Virchows Archiv"},{"key":"11006_CR74","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2147\/OTT.S34670","volume":"6","author":"JA Castellanos","year":"2013","unstructured":"Castellanos, J. A., Merchant, N. B., & Nagathihalli, N. S. (2013). Emerging targets in pancreatic cancer: Epithelial-mesenchymal transition and cancer stem cells. Onco Targets Ther, 6, 1261\u20131267. https:\/\/doi.org\/10.2147\/OTT.S34670","journal-title":"Onco Targets Ther"},{"key":"11006_CR75","doi-asserted-by":"publisher","unstructured":"Neesse, A., et al. (2019). Stromal biology and therapy in pancreatic cancer: Ready for clinical translation? Gut, 68(1). https:\/\/doi.org\/10.1136\/gutjnl-2018-316451","DOI":"10.1136\/gutjnl-2018-316451"},{"issue":"10","key":"11006_CR76","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T., & Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nature Reviews. Clinical Oncology, 14(10), 611\u2013629. https:\/\/doi.org\/10.1038\/nrclinonc.2017.44","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"11006_CR77","doi-asserted-by":"publisher","unstructured":"Quan, M. Y. (2020). An FGFR\/AKT\/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness, Front. Cell Dev. Biol., vol. 8, no. October, pp. 10\u201313. https:\/\/doi.org\/10.3389\/fcell.2020.00287","DOI":"10.3389\/fcell.2020.00287"},{"issue":"7","key":"11006_CR78","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/cas.12691","volume":"106","author":"J Neradil","year":"2015","unstructured":"Neradil, J., & Veselska, R. (2015). Nestin as a marker of cancer stem cells. Cancer Science, 106(7), 803\u2013811. https:\/\/doi.org\/10.1111\/cas.12691","journal-title":"Cancer Science"},{"key":"11006_CR79","doi-asserted-by":"publisher","unstructured":"Wiese, C., et al. (Oct. 2004). Nestin expression\u2013a property of multi-lineage progenitor cells? Cellular and Molecular Life Sciences, 61, 19\u201320. https:\/\/doi.org\/10.1007\/s00018-004-4144-6","DOI":"10.1007\/s00018-004-4144-6"},{"issue":"8","key":"11006_CR80","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.micron.2011.04.005","volume":"42","author":"O Zarnescu","year":"2011","unstructured":"Zarnescu, O., Brehar, F. M., Bleotu, C., & Gorgan, R. M. (2011). Co-localization of PCNA, VCAM-1 and caspase-3 with Nestin in xenografts derived from human anaplastic Astrocytoma and glioblastoma multiforme tumor spheres. Micron (Oxford, England : 1993), 42(8), 793\u2013800. https:\/\/doi.org\/10.1016\/j.micron.2011.04.005","journal-title":"Micron (Oxford, England : 1993)"},{"issue":"2","key":"11006_CR81","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neo.2018.09.008","volume":"21","author":"CC Ti\u00e8che","year":"2019","unstructured":"Ti\u00e8che, C. C., et al. (2019). Tumor initiation capacity and therapy resistance are differential features of EMT-Related subpopulations in the NSCLC cell line A549. Neoplasia (United States), 21(2), 185\u2013196. https:\/\/doi.org\/10.1016\/j.neo.2018.09.008","journal-title":"Neoplasia (United States)"},{"key":"11006_CR82","doi-asserted-by":"publisher","unstructured":"Zhu, Y., et al. (May 2021). SOX2 promotes chemoresistance, cancer stem cells properties, and epithelial\u2013mesenchymal transition by \u03b2-catenin and Beclin1\/autophagy signaling in colorectal cancer. Cell Death and Disease, 12(5). https:\/\/doi.org\/10.1038\/s41419-021-03733-5","DOI":"10.1038\/s41419-021-03733-5"},{"issue":"10","key":"11006_CR83","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/s41388-018-0553-0","volume":"38","author":"Y Jia","year":"2019","unstructured":"Jia, Y., et al. (2019). The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Oncogene, 38(10), 1764\u20131777. https:\/\/doi.org\/10.1038\/s41388-018-0553-0","journal-title":"Oncogene"},{"issue":"9","key":"11006_CR84","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3748\/wjg.v20.i9.2247","volume":"20","author":"M Herreros-Villanueva","year":"2014","unstructured":"Herreros-Villanueva, M., Bujanda, L., Billadeau, D. D., & Zhang, J. S. (2014). Embryonic stem cell factors and pancreatic cancer. World Journal of Gastroenterology, 20(9), 2247\u20132254. https:\/\/doi.org\/10.3748\/wjg.v20.i9.2247","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"11006_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-016-0387-y","volume":"35","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y., et al. (2016). Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance. Journal of Experimental & Clinical Cancer Research : Cr, 35(1), 1\u201312. https:\/\/doi.org\/10.1186\/s13046-016-0387-y","journal-title":"Journal of Experimental & Clinical Cancer Research : Cr"},{"key":"11006_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.01367","volume":"10","author":"K Sone","year":"2020","unstructured":"Sone, K., et al. (2020). Nestin expression affects resistance to chemotherapy and clinical outcome in small cell lung cancer. Frontiers in Oncology, 10, 1\u20139. https:\/\/doi.org\/10.3389\/fonc.2020.01367","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"11006_CR87","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/MPA.0000000000001828","volume":"50","author":"R Mu","year":"2021","unstructured":"Mu, R., et al. (2021). Hypoxia promotes pancreatic cancer cell dedifferentiation to Stem-Like cell phenotypes with high tumorigenic potential by the HIF-1\u03b1\/Notch signaling pathway. Pancreas, 50(5), 756\u2013765. https:\/\/doi.org\/10.1097\/MPA.0000000000001828","journal-title":"Pancreas"},{"key":"11006_CR88","doi-asserted-by":"publisher","unstructured":"Firat, E., & Niedermann, G. (2016). FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K\/mTOR inhibition, Oncotarget, vol. 7, no. 34, pp. 54883\u201354896. https:\/\/doi.org\/10.18632\/oncotarget.10702","DOI":"10.18632\/oncotarget.10702"},{"key":"11006_CR89","doi-asserted-by":"publisher","unstructured":"Zhang, Y., et al. (2018). Nuclear Nestin deficiency drives tumor senescence via lamin A\/C-dependent nuclear deformation. Nature Communications, 9(1). https:\/\/doi.org\/10.1038\/s41467-018-05808-y","DOI":"10.1038\/s41467-018-05808-y"},{"key":"11006_CR90","doi-asserted-by":"publisher","unstructured":"Yeh, D. W., Huang, L. R., Chen, Y. W., Huang, C. Y. F., & Chuang, T. H. (2016). Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling, Journal of Immunology Research, vol. Hindawi Limited, 2016. https:\/\/doi.org\/10.1155\/2016\/4368101","DOI":"10.1155\/2016\/4368101"},{"key":"11006_CR91","doi-asserted-by":"publisher","unstructured":"Lengerke, C., et al. (Jan. 2011). Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. Bmc Cancer, 11. https:\/\/doi.org\/10.1186\/1471-2407-11-42","DOI":"10.1186\/1471-2407-11-42"},{"issue":"1","key":"11006_CR92","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41420-024-01871-1","volume":"10","author":"S Roy","year":"2024","unstructured":"Roy, S., et al. (2024). SOX2 and OCT4 mediate radiation and drug resistance in pancreatic tumor organoids. Cell Death Discov, 10(1), 2\u20139. https:\/\/doi.org\/10.1038\/s41420-024-01871-1","journal-title":"Cell Death Discov"},{"issue":"1","key":"11006_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-023-02883-y","volume":"42","author":"Q Zheng","year":"2023","unstructured":"Zheng, Q., et al. (2023). Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2\/MYC signaling and restoring chemosensitivity. Journal of Experimental & Clinical Cancer Research : Cr, 42(1), 1\u201321. https:\/\/doi.org\/10.1186\/s13046-023-02883-y","journal-title":"Journal of Experimental & Clinical Cancer Research : Cr"},{"key":"11006_CR94","doi-asserted-by":"publisher","unstructured":"Yeh, D. W., Huang, L. R., Chen, Y. W., Huang, C. Y. F., & Chuang, T. H. (2016). Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling, J. Immunol. Res., vol. 2016. https:\/\/doi.org\/10.1155\/2016\/4368101","DOI":"10.1155\/2016\/4368101"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-025-11006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-025-11006-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-025-11006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:21:31Z","timestamp":1768342891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-025-11006-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["11006"],"URL":"https:\/\/doi.org\/10.1007\/s12015-025-11006-3","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All of the authors are aware of and agree to the content of the paper and their being listed as an author on the paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent To Participate"}}]}}